Protein Spotlight 208

Rvx 208

RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therap...

A Spotlight on Spotlight

In this paper, we have made an attempt to take a look under the hood of Spotlight and understand some of the following questions amongst others: • How well-integrated is Spotlight with the file system? • How reliable is the interface between Spotlight and the file system? • Is live update a myth or a reality under heavy file system activity? Based on our experiments, it seems that Spotlight is ...

208 C*-algebras

Op-brhe140040 208..209

The introduction of TNF inhibitors more than a decade ago marked the beginning of an exciting era in the management of RA. Despite the development of biologics with alternative modes of action, TNF inhibitors remain today the most widely prescribed class of biologics for RA. However, tuberculosis (TB) is a major safety concern with TNF inhibitors. The risk of active TB is increased up to 56-fol...

Leg 208 Preliminary Report

This report was prepared from shipboard files by scientists who participated in the cruise. The report was assembled under time constraints and does not contain all works and findings that will appear in the DISCLAIMER Any opinions, findings, and conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the National Scien...